Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Brain+ announces that 58% of its warrants of series TO 3 are covered by early commitments

COMPANY ANNOUNCEMENT · Members of management and board members/observers have committed to exercise all their TO 3 warrants and provide additional guarantee commitments, covering 6% of the issue   · The company’s largest shareholders have so far provided firm commitments to exercise warrants and provide guarantees for a total of 52% of the issue · As earlier announced, the exercise price for the warrants of series TO 3 is DKK 0.11 and the exercise period runs from 11 March 2024 to 22 March 2024 · If all warrants are exercised/guaranteed, it will add DKK 3.14 million and three (3)

Fiskars Corporation’s directed share issue without consideration based on the Performance Share Plan

Fiskars CorporationStock Exchange ReleaseMarch 11, 2024 at 1.50 p.m. EET Fiskars Corporation’s directed share issue without consideration based on the Performance Share Plan The Board of Directors of Fiskars Corporation has decided on a directed share issue without consideration based on Fiskars Group’s Performance Share Plan in order to pay the share rewards for the plan period 2021–2023. In the share issue, 73,381 treasury shares are issued without consideration to the key personnel participating in the plan period 2021–2023, in accordance with the terms and conditions of the

Elkem focuses on core business, exits Vianode

Oslo, 11 March 2024 Elkem has decided to exit its financial investment in the advanced battery materials company Vianode. This is in line with the previously announced comprehensive programme for earnings improvements and capex reductions in Elkem, and a focus on Elkem’s core business. Going forward, Vianode will continue to be backed by global aluminium and renewable energy company Hydro and Altor Fund V, a fund managed by Altor Fund Manager. Through the highly skilled employees who have joined Vianode from Elkem since its founding in 2021, Vianode will continue to benefit from

AMSC ASA: Mandatory notification of trade

11 March 2024 - Peter D. Knudsen, board member of AMSC ASA ("AMSC" or the "Company"), has today acquired 4,000 shares in AMSC through the company Vilja AS. The price per share was NOK 24.4522, which implies a total consideration of NOK 97,808.80. Following the transaction, Vilja AS holds a total of 34,000 shares in AMSC, constituting approximately 0.047% of the Company's shares and votes. Please see attached primary insider notification form pursuant to the requirements of the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to

BioStock: BioInvent’s CEO comments on the study success in China

BioInvent’s partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent’s lead drug candidate BI-1206 in combination with rituximab in cancer patients with non-Hodgkin’s lymphoma. BioStock reached out to BioInvent’s CEO Martin Welschof, who expects that 2024 will be a break-out year for the company, with multiple data readouts expected during the second half of the year.Read the full interview with Martin Welschof at biostock.se: https://www.biostock.se/en/2024/03/bioinvents-ceo-comments-on-the-study-success-in-china/ This is a press

Volvo Group signs agreement with Westport for joint venture to reduce CO2 emissions from long haul transport

The Volvo Group has signed an agreement according to the previously announced Letter of Intent with Westport Fuel Systems Inc to establish a joint venture to accelerate the commercialization and global adoption of Westport’s High Pressure Direct Injection (HPDI[TM]) fuel system technology for long-haul and off-road applications.The closing of the joint venture is subject to certain closing conditions, including regulatory and government approvals. It is anticipated that the joint venture will become operational following the formal closing which is expected in the second quarter of 2024.

AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease

For Medical and Trade media. · Foslevodopa-foscarbidopa will soon be available for eligible patients with advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia in Scotland, providing an additional option when currently available combinations of treatments have not given satisfactory results[1] · Following the recommendation by the National Institute for Health and Care Excellence (NICE) in November 2023, this means foslevodopa-foscarbidopa will soon be available for use within the NHS across the UK[2] · The advice from the

Notice of Annual General Meeting in Sleep Cycle AB (publ)

The shareholders of Sleep Cycle AB (publ) (“Sleep Cycle”), reg. no. 556614-7368, are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on 11 April 2024 at 09:30 CEST at Jacy’z hotel, floor 24, Drakegatan 10, 412 50 Gothenburg, Sweden. Admission and registration for the AGM will begin at 09:00 CEST.The Board of Directors has resolved, in accordance with the provisions of Sleep Cycle’s Articles of Association, that shareholders may also exercise their voting rights in advance by so-called postal voting. Right to participate and notification A) Attending the

Sivers Semiconductors announces an expanded loan facility of SEK 50 million

With this financing, the Company has secured funding for continued growthKista, Sweden // Mar. 11, 2024 // Sivers Semiconductors AB (STO: SIVE), (the "Company"), a leading supplier of integrated chips and modules for the most advanced communications and sensor solutions, has, according to previous communication in connection with the 2023 fourth-quarter report, agreed to entered into a loan agreement with Formue Nord and partners extending the previous SEK 75 million facility. The new SEK 50 million loan facility includes a SEK 35 million convertible loan at a fixed conversion rate of 4.86

Gaming Innovation Group - Mandatory notification of trade

Mikael Riese Harstad, board member and primary insider of Gaming Innovation Group Inc. (GiG), has today transferred 477,733 shares in GiG without consideration to his wife Helena Riese Harstad. This transaction will not change the number of shares held by Harstad and close associates, and after this transaction, Harstad and close associates owns 1,342,136 shares in GiG. For further information, contact: Tore Formo, Group CFO, tore@gig.com +47 916 68 678 This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Spinomenal Enhances 888 Collaboration with Italian Expansion

Spinomenal, the leading iGaming content provider, has amplified its Italian iGaming presence thanks to a new content partnership with 888 Italy. Spinomenal’s titles are being integrated via Pariplay’s aggregation platform, Fusion.Spinomenal made its debut in the Italian market in the summer and it has become an important region for the business. Players using 888 Italy will be able to enjoy a wide selection of games, including the hugely popular Majestic King, Book of Demi Gods 2, Egyptian Rebirth and many others.Italy joins the list of already established markets, including UK, Romania,

ColdZyme® certified under the new EU medical device regulation (MDR)

Enzymatica’s mouth spray ColdZyme® has received CE-certification under the new and more demanding European Union medical device regulation (MDR). This important milestone validates the company’s scientific data and extends product claims throughout the EU. The certification is a key pillar for expansion in several markets and is expected to have long-term positive effects on Enzymatica’s growth. Eurofins, a European approved notified body for medical devices, has certified the ColdZyme® product line MDR (class III) according to the European Union medical device regulation. MDR replaces

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BR0WHY71 Issuer Name ACUITY RM GROUP PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Jonathan Mark Swann City of registered office (if applicable) rickmansworth Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification

Inside information: Outokumpu downgrades its guidance for Q1 2024 – adjusted EBITDA expected to be at a similar or lower level compared to Q4 2023 due to the political strike in Finland

Outokumpu OyjInside informationMarch 11, 2024 at 12.15 pm EETInside information: Outokumpu downgrades its guidance for Q1 2024 – adjusted EBITDA expected to be at a similar or lower level compared to Q4 2023 due to the political strike in Finland Outokumpu downgrades its guidance for the first quarter of 2024 due to the political strike in Finland. The political strike is aimed against the Finnish government and is not related to Outokumpu’s labor relations. Majority of Outokumpu’s stainless steel and ferrochrome operations as well as Tornio port in Finland will be shut down for

Acquisitions of own shares in Evolution AB (publ)

Evolution AB (publ) (“Evolution”) has, during the period 04 March – 08 March acquired a total of 259,324 own shares within the framework of the repurchase programme introduced by the board of directors to improve the capital structure of Evolution by reducing the capital, and thereby creating added shareholder value.The repurchase programme, which Evolution announced on 23 November 2023, is being implemented in accordance with the EU Market Abuse Regulation No 596/2014 (“MAR”) and Commission Delegated Regulation No 2016/1052 (“Safe Harbour Regulation”). During the period 04 March – 08

Nordic Mining ASA: Key information relating to the reverse split and change of ISIN

Key information relating to the reverse split resolved by the Extraordinary General Meeting on 11 March 2024:   Date on which the terms and conditions of the share consolidation was made public: 19 February 2024 Reverse split ratio: 20 old shares give 1 new share Last day including right: 12 March 2024 Ex-date: 13 March 2024 Record date: 14 March 2024 Date of approval: 11 March 2024   In connection with the share consolidation, the Company's shares will be transferred to a new ISIN. Please find below the following key information for the change of ISIN: Issuer:

Nordic Mining ASA: Reverse split resolved by the Extraordinary General Meeting

The Extraordinary General Meeting in Nordic Mining ASA was held Monday 11 March 2024. All agenda items were approved in line with the proposals in the Extraordinary General Meeting notice. See separate press release with key information relating to the reverse split resolved by the Extraordinary General Meeting. The minutes from the Extraordinary General Meeting in Norwegian and English are attached. For further information, please contact CFO Jens Gisle Schnelle, telephone +47 476 60 355 Oslo, 11 March 2024Nordic Mining ASA This information is subject to the disclosure

Terveystalo Plc - Managers' transactions - Saviharju

Terveystalo Plc, Managers' transactions, 11 March 2024 at 11:48 a.m. EET This is a notification under the Market Abuse Regulation (MAR) that General Counsel Elina Saviharju has received shares in Terveystalo as part of the performance share plan 2021-2023. Person subject to the notification requirementName: Saviharju, ElinaPosition: Other senior managerIssuer: Terveystalo PlcLEI: 7437001AEZHLL3UEX093 Notification type: INITIAL NOTIFICATIONReference number: 7437001AEZHLL3UEX093_20240308135126_60____________________________________________ Transaction date: 2024-03-07

Terveystalo Plc - Managers' transactions - Mäenalanen

Terveystalo Plc, Managers' transactions, 11 March 2024 at 11:47 a.m. EET This is a notification under the Market Abuse Regulation (MAR) that EVP Henri Mäenalanen has received shares in Terveystalo as part of the performance share plan 2021-2023. Person subject to the notification requirementName: Mäenalanen, HenriPosition: Other senior managerIssuer: Terveystalo PlcLEI: 7437001AEZHLL3UEX093 Notification type: INITIAL NOTIFICATIONReference number: 7437001AEZHLL3UEX093_20240308135126_58____________________________________________ Transaction date: 2024-03-07Venue not

Terveystalo Plc - Managers' transactions - Pajunen

Terveystalo Plc, Managers' transactions, 11 March 2024 at 11:46 a.m. EET This is a notification under the Market Abuse Regulation (MAR) that CFO Juuso Pajunen has received shares in Terveystalo as part of the performance share plan 2021-2023. Person subject to the notification requirementName: Pajunen, JuusoPosition: Chief Financial OfficerIssuer: Terveystalo PlcLEI: 7437001AEZHLL3UEX093 Notification type: INITIAL NOTIFICATIONReference number: 7437001AEZHLL3UEX093_20240308135126_59____________________________________________ Transaction date: 2024-03-07Venue not

Terveystalo Plc - Managers' transactions - Iho

Terveystalo Plc, Managers' transactions, 11 March 2024 at 11:45 a.m. EET This is a notification under the Market Abuse Regulation (MAR) that President and CEO Ville Iho has received shares in Terveystalo as part of the performance share plan 2021-2023. Person subject to the notification requirementName: Iho, VillePosition: Chief Executive OfficerIssuer: Terveystalo PlcLEI: 7437001AEZHLL3UEX093 Notification type: INITIAL NOTIFICATIONReference number: 7437001AEZHLL3UEX093_20240308135126_57____________________________________________ Transaction date: 2024-03-07Venue

There are no items matching the current filter
There are no more items matching the current filter
Back to top